TTHX1114 (Topical Eye Drops)
Corneal epithelial damage (e.g., persistent epithelial defects, neurotrophic keratitis)
Key Facts
About Trefoil Therapeutics
Trefoil Therapeutics is a private, clinical-stage biotech founded in 2012 and based in San Diego, focused on first-in-class treatments for corneal diseases. Its core asset is TTHX1114, an engineered, stabilized form of FGF1, which is being advanced in two distinct programs: an intracameral injection for endothelial conditions like Fuchs Endothelial Corneal Dystrophy (FECD) and a topical eye drop for epithelial damage. The company has raised $45 million in venture financing, secured non-dilutive funding from the NIH and DoD, and has reported positive Phase 2 data for its endothelial program, positioning it to address a significant unmet need in ophthalmology with a novel regenerative approach.
View full company profile